Recent structural advances of β1 and β2 adrenoceptors yield keys for ligand recognition and drug design

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8207-8223

  Soriano Ursúa, Marvin A ^a   Trujillo Ferrara, José G ^a   Correa Basurto, José ^a   Vilar, Santiago ^b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ADRENALIN; ALPRENOLOL; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARAZOLOL; CARMOTEROL; CARVEDILOL; CIMATEROL; CLENBUTEROL; DOBUTAMINE; DOPAMINE; FAUC 50; FENOTEROL; FORMOTEROL; IB 167107; ISOETARINE; ISOPRENALINE; LABETALOL; METOPROLOL; MILVETEROL; NORADRENALIN; PINDOLOL; PROCATEROL; PROPRANOLOL; SALBUTAMOL; SALMETEROL; TERBUTALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

BINDING SITE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; HUMAN; LIGAND BINDING; REVIEW; X RAY;

DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84886444707     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400471z     Document Type: Review

References (180)

1. Kobilka, B. K. Structural insights into adrenergic receptor function and pharmacology Trends Pharmacol. Sci. 2011, 32, 213-218
2. Congreve, M.; Marshall, F. The impact of GPCR structures on pharmacology and structure-based drug design Br. J. Pharmacol. 2010, 159, 986-996
3. Taira, C. A.; Carranza, A.; Mayer, M.; Di Verniero, C.; Opezzo, A.; Höcht, C. Therapeutic implication of beta-adrenergic receptor pharmacodynamic properties Curr. Clin. Pharm. 2008, 3, 174-184
4. Limbird, L. E. Historical perspective for understanding of adrenergic receptors Curr. Top. Membr. 2011, 67, 1-17
5. Dixon, R. A.; Kobilka, B. K.; Strader, D. J.; Benovic, J. L.; Dohlman, H. G.; Frielle, T.; Bolanowski, M. A.; Bennett, C. D.; Rands, E.; Diehl, R. E.; Mumford, R. A.; Slater, E. E.; Sigal, I. S.; Caron, M. G.; Lefkowitz, R. J.; Strader, C. D. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin Nature 1986, 321, 75-79
6. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor Science 2000, 289, 739-745
7. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human β2 adrenergic G-protein-coupled receptor Nature 2007, 450, 383-387
8. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor Science 2007, 318, 1258-1265
9. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a β1-adrenergic G-protein-coupled receptor Nature 2008, 454, 486-491
10. Wacker, D.; Fenalti, G.; Brown, M. A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R.C. Conserved binding mode of human β2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography J. Am. Chem. Soc. 2010, 132, 11443-11445
11. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 2010, 330, 1091-1095
12. Rosenbaum, D. M.; Zhang, C.; Lyons, J. A.; Holl, R.; Aragao, D.; Arlow, D. H.; Rasmussen, S. G.; Choi, H. J.; Devree, B. T.; Sunahara, R. K.; Chae, P. S.; Gellman, S. H.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Caffrey, M.; Gmeiner, P.; Kobilka, B. K. Structure and function of an irreversible agonist-β(2) adrenoceptor complex Nature 2011, 469, 236-240
13. Rasmussen, S. G.; Choi, H. J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; Devree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; Schnapp, A.; Konetzki, I.; Sunahara, R. K.; Gellman, S. H.; Pautsch, A.; Steyaert, J.; Weis, W. I.; Kobilka, B. K. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor Nature 2011, 469, 175-180
14. Rasmussen, S. G.; DeVree, B. T.; Zou, Y.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; Mathiesen, J. M.; Shah, S. T.; Lyons, J. A.; Caffrey, M.; Gellman, S. H.; Steyaert, J.; Skiniotis, G.; Weis, W. I.; Sunahara, R. K.; Kobilka, B. K. Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature 2011, 477, 549-555
15. Warne, T.; Edwards, P. C.; Leslie, A. G.; Tate, C. G. Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol Structure 2012, 20, 841-849
16. Shoichet, B. K.; Kobilka, B. K. Structure-based drug screening for G-protein-coupled receptors Trends Pharmacol. Sci. 2012, 33, 268-272
17. Zocher, M.; Fung, J. J.; Kobilka, B. K.; Müller, D. J. Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β(2) adrenergic receptor Structure 2012, 20, 1391-1402
18. Katritch, V.; Cherezov, V.; Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 2013, 53, 531-556
19. Stevens, R. C.; Cherezov, V.; Katritch, V.; Abagyan, R.; Kuhn, P.; Rosen, H.; Wüthrich, K. The GPCR network: a large-scale collaboration to determine human GPCR structure and function Nat. Rev. Drug Discovery 2013, 12, 25-34
20. Kooistra, A. J.; Roumen, L.; Leurs, R.; de Esch, I. J.; de Graaf, C. From heptahelical bundle to hits from the haystack: structure-based virtual screening for GPCR ligands Methods Enzymol. 2013, 522, 279-336
21. Jacobson, K. A.; Costanzi, S. New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors Mol. Pharmacol. 2012, 82, 361-371
22. Mason, J. S.; Bortolato, A.; Congreve, M.; Marshall, F. H. New insights from structural biology into the druggability of G protein-coupled receptors Trends Pharmacol. Sci. 2012, 33, 249-260
23. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in structure based drug design for G proteincoupled receptors J. Med. Chem. 2011, 54, 4283-4311
24. Gao, Z. G.; Jacobson, K. A. Allosteric modulation and functional selectivity of G protein-coupled receptors Drug Discovery Today: Technol. 2013, 10, e237-e243
25. Wang, C.; Wu, H.; Katritch, V.; Han, G. W.; Huang, X. P.; Liu, W.; Siu, F. Y.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human smoothened receptor bound to an antitumour agent Nature 2013, 497, 338-343
26. Green, S. A.; Liggett, A. A proline-rich region in the third loop imparts phenotypic β1- versus β2-adrenergic receptor coupling and sequestration J. Biol. Chem. 1994, 269, 26215-26219
27. 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation Naunyn Schmiedeberg's Arch. Pharmacol. 1987, 335, 403-411
28. 2-adrenergic receptors Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10798-17802
29. i coupling Naunyn Schmiedeberg's Arch. Pharmacol. 2007, 375, 11-28
30. s-protein Circulation 2000, 102, 1814-1821
31. Huang, J.; Chen, S.; Zhang, J. J.; Huang, X. Y. Crystal structure of oligomeric β(1)-adrenergic G protein-coupled receptors in ligand-free basal state Nat. Struct. Mol. Biol. 2013, 20, 419-425
32. 2 adrenoceptor: description of two binding sites J. Mol. Model. 2011, 17, 2525-2538
33. Stallaert, W.; Dorn, J. F.; Westhuizen, E.; Audet, M.; Bouvier, M. Impedance responses reveal β2-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles PLoS One 2012, 7, e29420
34. 19F-NMR Science 2012, 335, 1106-1110
35. Soriano-Ursúa, M. A.; Trujillo-Ferrara, J. G.; Correa-Basurto, J. Scope and difficulty in generating theoretical insights regarding ligand recognition and activation of the beta 2 adrenergic receptor J. Med. Chem. 2010, 53, 923-932
36. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51
37. Bokoch, M. P.; Zou, Y.; Rasmussen, S. G.; Liu, C. W.; Nygaard, R.; Rosenbaum, D. M.; Fung, J. J.; Choi, H. J.; Thian, F. S.; Kobilka, T. S.; Puglisi, J. D.; Weis, W. I.; Pardo, L.; Prosser, R. S.; Mueller, L.; Kobilka, B. K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor Nature 2010, 463, 108-112
38. Peeters, M. C.; van Westen, G. J.; Li, Q.; IJzerman, A. P. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation Trends Pharmacol. Sci. 2011, 32, 35-42
39. Wheatley, M.; Wootten, D.; Conner, M. T.; Simms, J.; Kendrick, R.; Logan, R. T.; Poyner, D. R.; Barwell, J. Lifting the lid on GPCRs: the role of extracellular loops Br. J. Pharmacol. 2012, 165, 1688-1703
40. Katritch, V.; Cherezov, V.; Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures Trends Pharmacol. Sci. 2012, 33, 17-27
41. Tao, Y. X. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications Pharmacol. Ther. 2006, 111, 949-973
42. Clark, S. D.; Tran, H. T.; Zeng, J.; Reinscheid, R. K. Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function Peptides 2010, 31, 130-138
43. Härterich, S.; Koschatzky, S.; Einsiedel, J.; Gmeiner, P. Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1 Bioorg. Med. Chem. 2008, 16, 9359-9368
44. Peeters, M. C.; van Westen, G. J.; Guo, D.; Wisse, L. E.; Müller, C. E.; Beukers, M. W.; Ijzerman, A. P. GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor FASEB J. 2011, 25, 632-643
45. Klco, J. M.; Nikiforovich, G. V.; Baranski, T. J. Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop J. Biol. Chem. 2006, 281, 12010-12019
46. Hawtin, S. R.; Simms, J.; Conner, M.; Lawson, Z.; Parslow, R. A.; Trim, J.; Sheppard, A.; Wheatley, M. Charged extracellular residues, conserved throughout a G-protein-coupled receptor family, are required for ligand binding, receptor activation, and cell-surface expression J. Biol. Chem. 2006, 281, 38478-38488
47. Nawaratne, V.; Leach, K.; Felder, C. C.; Sexton, P. M.; Christopoulos, A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms J. Biol. Chem. 2010, 285, 19012-19021
48. Zhao, M. M.; Hwa, J.; Perez, D. M. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding Mol. Pharmacol. 1996, 50, 1118-1126
49. Peter, J. C.; Eftekhari, P.; Billiald, P.; Wallukat, G.; Hoebeke, J. scFv single chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor J. Biol. Chem. 2003, 278, 36740-36747
50. Jahns, R.; Boivin, V.; Hein, L.; Triebel, S.; Angermann, C. E.; Ertl, G.; Lohse, M. J. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy J. Clin. Invest. 2004, 113, 1419-1429
51. Abdelkrim, M. A.; Mallem, M. Y.; Chatagnon, G.; Gogny, M.; Desfontis, J. C.; Noireaud, J. Autoantibodies against cardiac β(1)-adrenoceptor do not affect the low-affinity state β(1)-adrenoceptor-mediated inotropy in rat cardiomyocytes Can. J. Physiol. Pharmacol. 2012, 90, 407-414
52. Yang, L.; Lin, H.; Xi, Q.; Ding, J.; Liu, X.; Shu, G.; Jiang, Q.; Wang, X.; Zhang, Y. Polyantibody against β2-adrenergic receptor extracellular domain act as an agonist to this receptor in porcine model Livest. Sci. 2012, 150, 248-255
53. Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D. W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 13118-13123
54. Vilar, S.; Karpiak, J.; Berk, B.; Costanzi, S. In silico analysis of the binding of agonists and blockers to the β2-adrenergic receptor J. Mol. Graphics Modell. 2011, 29, 809-817
55. Massotte, D.; Kieffer, B. L. The second extracellular loop: a damper for G protein-coupled receptors? Nat. Struct. Mol. Biol. 2005, 12, 287-288
56. Klco, J. M.; Wiegand, C. B.; Narzinski, K.; Baranski, T. J. Essential role for the second extracellular loop in C5a receptor activation Nat. Struct. Mol. Biol. 2005, 12, 320-326
57. Costanzi, S.; Joshi, B. V.; Maddileti, S.; Mamedova, L.; Gonzalez-Moa, M. J.; Marquez, V. E.; Harden, T. K.; Jacobson, K. A. Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference J. Med. Chem. 2005, 48, 8108-8111
58. Kim, J. H.; Jiang, Q. L.; Glashofer, M.; Yehle, S.; Wess, J.; Jacobson, K. A. Glutamate residues in the second extracellular loop of the humanA(2a) adenosine receptor are required for ligand recognition Mol. Pharmacol. 1996, 49, 683-691
59. Tikhonova, I. G.; Sum, C. S.; Neumann, S.; Thomas, C. J.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Bidirectional, iterative approach to the structural delineation of the functional "Chemoprint" in GPR40 for agonist recognition J. Med. Chem. 2007, 50, 2981-2989
60. Kleinau, G.; Claus, M.; Jaeschke, H.; Mueller, S.; Neumann, S.; Paschke, R.; Krause, G. Contacts between extracellular loop two and transmembrane helix six determine basal activity of the thyroid-stimulating hormone receptor J. Biol. Chem. 2007, 282, 518-525
61. Shi, L.; Javitch, J. A. The second extracellular loop of the dopamine D-2 receptor lines the binding-site crevice Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 440-445
62. Ahuja, S.; Hornak, V.; Yan, E. C.; Syrett, N.; Goncalves, J. A.; Hirshfeld, A.; Ziliox, M.; Sakmar, T. P.; Sheves, M.; Reeves, P. J.; Smith, S. O.; Eilers, M. Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation Nat. Struct. Mol. Biol. 2009, 16, 168-175
63. Olah, M.; Jacobson, K.; Stiles, G. Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors J. Biol. Chem. 1994, 269, 24692-24698
64. Avlani, V. A.; Gregory, K. J.; Morton, C. J.; Parker, M. W.; Sexton, P. M.; Christopoulos, A. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands J. Biol. Chem. 2007, 282, 25677-25686
65. Zhao, M. M.; Gaivin, R. J.; Perez, D. M. The third extracellular loop of the beta2-adrenergic receptor can modulate receptor/G protein affinity Mol. Pharmacol. 1998, 53, 524-529
66. Lawson, Z.; Wheatley, M. The third extracellular loop of G-protein-coupled receptors: more than just a linker between two important transmembrane helices Biochem. Soc. Trans. 2004, 32, 1048-1050
67. Claus, M.; Jaeschke, H.; Kleinau, G.; Neumann, S.; Krause, G.; Paschke, R. A hydrophobic cluster in the center of the third extracellular loop is important for thyrotropin receptor signaling Endocrinology 2005, 146, 5197-5203
68. Décaillot, F. M.; Befort, K.; Filliol, D.; Yue, S.; Walker, P.; Kieffer, B. L. Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation Nat. Struct. Biol. 2003, 10, 629-636
69. Gregory, K. J.; Hall, N. E.; Tobin, A. B.; Sexton, P. M.; Christopoulos, A. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias J. Biol. Chem. 2010, 285, 7459-7474
70. Nygaard, R.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Schwartz, T. W. Ligand binding and micro-switches in 7TM receptor structures Trends Pharmacol. Sci. 2009, 30, 249-259
71. Canals, M.; Sexton, P. M.; Christopoulos, A. Allostery in GPCRs: "MWC" revisited Trends Biochem. Sci. 2011, 36, 663-672
72. De Amici, M.; Dallanoce, C.; Holzgrabe, U.; Tränkle, C.; Mohr, K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med. Res. Rev. 2010, 30, 463-549
73. Wootten, D.; Savage, E. E.; Valant, C.; May, L. T.; Sloop, K. W.; Ficorilli, J.; Showalter, A. D.; Willard, F. S.; Christopoulos, A.; Sexton, P. M. Allosteric modulation of endogenous metabolites as an avenue for drug discovery Mol. Pharmacol. 2012, 82, 281-290
74. Fredriksson, R.; Lagerström, M. C.; Lundin, L. G.; Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol. Pharmacol. 2003, 63, 1256-1272
75. Burford, N. T.; Watson, J.; Bertekap, R.; Alt, A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors Biochem. Pharmacol. 2011, 81, 691-702
76. Urwyler, S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 2011, 63, 59-126
77. de Graaf, C.; Rein, C.; Piwnica, D.; Giordanetto, F.; Rognan, D. Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors ChemMedChem 2011, 6, 2159-2169
78. Niesen, M. J.; Bhattacharya, S.; Vaidehi, N. The role of conformational ensembles in ligand recognition in G-protein coupled receptors J. Am. Chem. Soc. 2011, 133, 13197-13204
79. Smith, N. J.; Bennett, K. A.; Milligan, G. When simple agonism is not enough: emerging modalities of GPCR ligands Mol. Cell. Endocrinol. 2011, 331, 241-247
80. 2+ Mol. Pharmacol. 2002, 61, 65-72
81. Fuxe, K.; Borroto-Escuela, D. O.; Marcellino, D.; Romero-Fernandez, W.; Frankowska, M.; Guidolin, D.; Filip, M.; Ferraro, L.; Woods, A. S.; Tarakanov, A.; Ciruela, F.; Agnati, L. F.; Tanganelli, S.. GPCR heteromers and their allosteric receptor-receptor interactions Curr. Med. Chem. 2012, 19, 356-363
82. Smith, N. J.; Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Pharmacol. Rev. 2010, 62, 701-725
83. Kratochwil, N. A.; Gatti-McArthur, S.; Hoener, M. C.; Lindemann, L.; Christ, A. D.; Green, L. G.; Guba, W.; Martin, R. E.; Malherbe, P.; Porter, R. H.; Slack, J. P.; Winnig, M.; Dehmlow, H.; Grether, U.; Hertel, C.; Narquizian, R.; Panousis, C. G.; Kolczewski, S.; Steward, L. G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey Curr. Top. Med. Chem. 2011, 11, 1902-1924
84. Kaumann, A. J.; Molenaar, P. The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology Pharmacol. Ther 2008, 118, 303-336
85. Isogaya, M.; Sugimoto, Y.; Tanimura, R.; Tanaka, R.; Kikkawa, H.; Nagao, T.; Kurose, H. Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists Mol. Pharmacol. 1999, 56, 875-885
86. Green, S. A.; Rathz, D. A.; Schuster, A. J.; Liggett, S. B. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s) Eur. J. Pharmacol. 2001, 421, 141-147
87. Szczuka, A.; Wennerberg, M.; Packeu, A.; Vauquelin, G. Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol Br. J. Pharmacol. 2009, 158, 183-194
88. González, A.; Perez-Acle, T.; Pardo, L.; Deupi, X. Molecular basis of ligand dissociation in beta-adrenergic receptors PLoS One 2011, 6, e23815
89. Unal, H.; Karnik, S. S. Domain coupling in GPCRs: the engine for induced conformational changes Trends Pharmacol. Sci. 2012, 33, 79-88
90. Mary, S.; Damian, M.; Louet, M.; Floquet, N.; Fehrentz, J. A.; Marie, J.; Martinez, J.; Banères, J. L. Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 8304-8309
91. Bockenhauer, S.; Fürstenberg, A.; Yao, X. J.; Kobilka, B. K.; Moerner, W. E. Conformational dynamics of single G protein-coupled receptors in solution J. Phys. Chem. B 2011, 115, 13328-13338
92. Moukhametzianov, R.; Warne, T.; Edwards, P. C.; Serrano-Vega, M. J.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 8228-8232
93. Dror, R. O.; Arlow, D. H.; Maragakis, P.; Mildorf, T. J.; Pan, A. C.; Xu, H.; Borhani, D. W.; Shaw, D. E. Activation mechanism of the β2-adrenergic receptor Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 18684-18689
94. Trzaskowski, B.; Latek, D.; Yuan, S.; Ghoshdastider, U.; Debinski, A.; Filipek, S. Action of molecular switches in GPCRs-theoretical and experimental studies Curr. Med. Chem. 2012, 19, 1090-1109
95. Fanelli, F.; De Benedetti, P. G. Update 1 of: computational modeling approaches to structure-function analysis of G protein-coupled receptors Chem. Rev. 2011, 111, PR438-PR535
96. Arch, J. R. Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine? Br. J. Pharmacol. 2004, 143, 517-518
97. Molenaar, P.; Chen, L.; Semmler, A. B.; Parsonage, W. A.; Kaumann, A. J. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through "affinity states" and polymorphism Clin. Exp. Pharmacol. Physiol. 2007, 34, 1020-1028
98. Heubach, J. F.; Ravens, U.; Kaumann, A. J. Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart Mol. Pharmacol. 2004, 65, 1313-1322
99. Goetz, A.; Lanig, H.; Gmeiner, P.; Clark, T. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor J. Mol. Biol. 2011, 414, 611-623
100. Audet, M.; Bouvier, M. Insights into signaling from the beta2-adrenergic receptor structure Nat. Chem. Biol. 2008, 4, 397-403
101. Costanzi, S.; Vilar, S. In silico screening for agonists and blockers of the β(2) adrenergic receptor: implications of inactive and activated state structures J. Comput. Chem. 2012, 33, 561-572
102. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467
103. Liapakis, G.; Ballesteros, J. A.; Papachristou, S.; Chan, W. C.; Chen, X.; Javitch, J. A. The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor J. Biol. Chem. 2000, 275, 37779-37788
104. Kikkawa, H.; Isogaya, M.; Nagao, T.; Kurose, H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005 Mol. Pharmacol. 1998, 53, 128-134
105. Suryanarayana, S.; Kobilka, B. K. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand binding specificity Mol. Pharmacol. 1993, 44, 111-114
106. Strader, C. D.; Sigal, I. S.; Dixon, R. A. Structural basis of beta-adrenergic receptor function FASEB J. 1989, 3, 1825-1832
107. Joseph, S. S.; Colledge, W. H.; Kaumann, A. J. Aspartate138 is required for the high-affinity ligand binding site but not for the low-affinity binding site of the beta1-adrenoceptor Naunyn Schmiedeberg's Arch. Pharmacol. 2004, 370, 223-226
108. Jack, D. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoceptor agonists Br. J. Clin. Pharmacol. 1991, 31, 501-514
109. Coleman, R. A. On the mechanism of the persistent action of salmeterol: What is the current position? Br. J. Pharmacol. 2009, 158, 180-182
110. Jozwiak, K.; Woo, A. Y.; Tanga, M. J.; Toll, L.; Jimenez, L.; Kozocas, J. A.; Plazinska, A.; Xiao, R. P.; Wainer, I. W. Comparative molecular field analysis of fenoterol derivatives: a platform towards highly selective and effective beta(2)-adrenergic receptor agonists Bioorg. Med. Chem. 2010, 18, 728-736
111. Luttrell, L. M.; Kenakin, T. P. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling Methods Mol. Biol. 2011, 756, 3-35
112. Sprang, S. R.; Elk, J. C. Cell signaling. Structural origins of receptor bias Science 2012, 335, 1055-1056
113. Nobles, K. N.; Xiao, K.; Ahn, S.; Shukla, A. K.; Lam, C. M.; Rajagopal, S.; Strachan, R. T.; Huang, T. Y.; Bressler, E. A.; Hara, M. R.; Shenoy, S. K.; Gygi, S. P.; Lefkowitz, R. J. Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin Sci. Signaling 2011, 4, ra51
114. Casella, I.; Ambrosio, C.; Grò, M. C.; Molinari, P.; Costa, T. Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling Biochem. J. 2011, 438, 191-202
115. Zhu, W.; Petrashevskaya, N.; Ren, S.; Zhao, A.; Chakir, K.; Gao, E.; Chuprun, J. K.; Wang, Y.; Talan, M.; Dorn, G. W., 2nd; Lakatta, E. G.; Koch, W. J.; Feldman, A. M.; Xiao, R. P. Gi-biased ADRB2 signaling links GRK2 upregulation to heart failure Circ. Res. 2012, 110, 265-274
116. Zhu, W.; Zeng, X.; Zheng, M.; Xiao, R. P. The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly Circ. Res. 2005, 97, 507-509
117. Shenoy, S. K.; Drake, M. T.; Nelson, C. D.; Houtz, D. A.; Xiao, K.; Madabushi, S.; Reiter, E.; Premont, R. T.; Lichtarge, O.; Lefkowitz, R. J. beta-Arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor J. Biol. Chem. 2006, 281, 1261-1273
118. Casella, I.; Ambrosio, C.; Grò, M. C.; Molinari, P.; Costa, T. Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling Biochem. J. 2011, 438, 191-202
119. Shukla, A. K.; Manglik, A.; Kruse, A. C.; Xiao, K.; Reis, R. I.; Tseng, W. C.; Staus, D. P.; Hilger, D.; Uysal, S.; Huang, L. Y.; Paduch, M.; Tripathi-Shukla, P.; Koide, A.; Koide, S.; Weis, W. I.; Kossiakoff, A. A.; Kobilka, B. K.; Lefkowitz, R. J. Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide Nature 2013, 497, 137-141
120. Kim, Y. J.; Hofmann, K. P.; Ernst, O. P.; Scheerer, P.; Choe, H. W.; Sommer, M. E. Crystal structure of pre-activated arrestin p44 Nature 2013, 497, 142-146
121. Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M.; Siu, F. Y.; Liu, W.; Xu, H. E.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Structural features for functional selectivity at serotonin receptors Science 2013, 340, 615-619
122. Steen, A.; Thiele, S.; Guo, D.; Hansen, L. S.; Frimurer, T. M.; Rosenkilde, M. M. Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7 J. Biol. Chem. 2013, 288, 12511-12521
123. Denis, C.; Saulière, A.; Galandrin, S.; Sénard, J. M.; Galés, C. Probing heterotrimeric G protein activation: applications to biased ligands Curr. Pharm. Des. 2012, 18, 128-144
124. Galandrin, S.; Bouvier, M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy Mol. Pharmacol. 2006, 70, 1575-1584
125. Katritch, V.; Reynolds, K. A.; Cherezov, V.; Hanson, M. A.; Roth, C. B.; Yeager, M.; Abagyan, R. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes J. Mol. Recognit. 2009, 22, 307-318
126. Warne, T.; Moukhametzianov, R.; Baker, J. G.; Nehmé, R.; Edwards, P. C.; Leslie, A. G.; Schertler, G. F.; Tate, C. G. The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor Nature 2011, 469, 241-244
127. Galandrin, S.; Oligny-Longpré, G.; Bonin, H.; Ogawa, K.; Galés, C.; Bouvier, M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor Mol. Pharmacol. 2008, 74, 162-172
128. Kaya, A. I.; Onaran, H. O.; Özcan, G.; Ambrosio, C.; Costa, T.; Balli, S.; Ugur, Ö. Cell contact-dependent functional selectivity of β2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation J. Biol. Chem. 2012, 287, 6362-6374
129. Katritch, V.; Abagyan, R. GPCR agonist binding revealed by modeling and crystallography Trends Pharmacol. Sci. 2011, 32, 637-643
130. Soriano-Ursúa, M. A.; Trujillo-Ferrara, J. G.; Alvarez-Cedillo, J.; Correa-Basurto, J. Docking studies on a refined human beta(2) adrenoceptor model yield theoretical affinity values in function with experimental values for R -ligands, but not for S -antagonists J. Mol. Model. 2010, 16, 401-409
131. Butcher, A. J.; Kong, K. C.; Prihandoko, R.; Tobin, A. B. Physiological role of G-protein coupled receptor phosphorylation Handb. Exp. Pharmacol. 2012, 208, 79-94
132. Jacobsen, J. R.; Choi, S. K.; Combs, J.; Fournier, E. J.; Klein, U.; Pfeiffer, J. W.; Thomas, G. R.; Yu, C.; Moran, E. J. A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD Bioorg. Med. Chem. Lett. 2012, 22, 1213-1218
133. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.; Box, P. C.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Emmons, A.; Ford, A. J.; Holmes, D. S.; Horsley, H.; Kerr, F.; Li-Kwai-Cheung, A. M.; Looker, B. E.; Mann, I. S.; McLay, I. M.; Morrison, V. S.; Mutch, P. J.; Smith, C. E.; Tomlin, P. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach J. Med. Chem. 2010, 53, 4522-4530
134. Alcaraz, L.; Bailey, A.; Cadogan, E.; Connolly, S.; Jewell, R.; Jordan, S.; Kindon, N.; Lister, A.; Lawson, M.; Mullen, A.; Dainty, I.; Nicholls, D.; Paine, S.; Pairaudeau, G.; Stocks, M. J.; Thorne, P.; Young, A. From libraries to candidate: the discovery of new ultra long-acting dibasic β2-adrenoceptor agonists Bioorg. Med. Chem. Lett. 2012, 22, 689-695
135. Shan, W. J.; Huang, L.; Zhou, Q.; Jiang, H. L.; Luo, Z. H.; Lai, K. F.; Li, X.S.. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD Bioorg. Med. Chem. Lett. 2012, 22, 1523-1526
136. Fichna, J.; Perlikowska, R.; WyreÌ̈bska, A.; Gach, K.; Piekielna, J.; do-Rego, J. C.; Toth, G.; Kluczyk, A.; Janecki, T.; Janecka, A. Effect of 2′,6′-dimethyl- l -tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs Bioorg. Med. Chem. 2011, 19, 6977-6981
137. Weltrowska, G.; Lemieux, C.; Chung, N. N.; Schiller, P. W. Cyclic enkephalin analogs containing various para-substituted phenylalanine derivatives in place of Tyr1 are potent opioid agonists J. Pept. Res. 2005, 65, 36-41
138. Goupil, E.; Laporte, S. A.; Hebert, T. E. Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations Mini-Rev. Med. Chem. 2012, 12, 817-830
139. Flordellis, C. S. The plasticity of the 7TMR signaling machinery and the search for pharmacological selectivity Curr. Pharm. Des. 2012, 18, 145-160
140. Baker, J. G. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors Br. J. Pharmacol. 2010, 160, 1048-1061
141. Pooput, C.; Rosemond, E.; Karpiak, J.; Deflorian, F.; Vilar, S.; Costanzi, S.; Wess, J.; Kirk, K. L. Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines Bioorg. Med. Chem. 2009, 17, 7987-7992
142. Cushny, A. R. The action of optical isomers: III. Adrenalin J. Physiol. 1908, 17, 130-138
143. Baker, J. G.; Hill, S. J.; Summers, R. J. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling Trends Pharmacol. Sci. 2011, 32, 227-234
144. Liggett, S. B.; Bouvier, M.; O'Dowd, B. F.; Caron, M. G.; Lefkowitz, R. J.; DeBlasi, A. Substitution of an extracellular cysteine in the beta 2-adrenergic receptor enhances agonist-promoted phosphorylation and receptor
145. Kikkawa, H.; Kurose, H.; Isogaya, M.; Sato, Y.; Nagao, T. Differential contribution of two serine residues of wild type and constitutively active beta2-adrenoceptors to the interaction with beta2-selective agonists Br. J. Pharmacol. 1997, 121, 1059-1064
146. Frielle, T.; Caron, M. G.; Lefkowitz, R. J. Properties of the beta 1- and beta 2-adrenergic receptor subtypes revealed by molecular cloning Clin. Chem. 1989, 35, 721-725
147. Behr, B.; Hoffmann, C.; Ottolina, G.; Klotz, K. N. Novel mutants of the human beta1-adrenergic receptor reveal amino acids relevant for receptor activation J. Biol. Chem. 2006, 281, 18120-18125
148. Roy, K. K.; Saxena, A. K. Structural basis for the β-adrenergic receptor subtype selectivity of the representative agonists and antagonists J. Chem. Inf. Model. 2011, 51, 1405-1422
149. Selvam, B.; Wereszczynski, J.; Tikhonova, I. G. Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity Chem. Biol. Drug Des. 2012, 80, 215-226
150. Kaszuba, K.; Róg, T.; Bryl, K.; Vattulainen, I.; Karttunen, M. Molecular dynamics simulations reveal fundamental role of water as factor determining affinity of binding of beta-blocker nebivolol to beta(2)-adrenergic receptor J. Phys. Chem. B 2010, 114, 8374-8386
151. Patil, P. N.; Li, C.; Kumari, V.; Hieble, J. P. Analysis of efficacy of chiral adrenergic agonists Chirality 2008, 20, 529-543
152. Soudjin, W.; Van Wijngaarden, I.; IJzerman, A. P. Stereoselectivity of drug-receptor interactions IDrugs 2003, 6, 43-56
153. Kern, C.; Meyer, T.; Droux, S.; Schollmeyer, D.; Miculka, C. Synthesis and pharmacological characterization of β2-adrenergic agonist enantiomers: zilpaterol J. Med. Chem. 2009, 52, 1773-1777
154. Milgrom, H. Levosalbutamol in the treatment of asthma Expert Opin. Pharmacother. 2006, 7, 1659-1668
155. Zuurmond, H. M.; Hessling, J.; Blüml, K.; Lohse, M.; Ijzerman, A. P. Study of interaction between agonists and asn293 in helix VI of human beta(2)-adrenergic receptor Mol. Pharmacol. 1999, 56, 909-916
156. Ambrosio, C.; Molinari, P.; Cotecchia, S.; Costa, T. Catechol-binding serines of β2-adrenergic receptors control the equilibrium between active and inactive receptor states Mol. Pharmacol. 2000, 57, 198-210
157. Swaminath, G.; Xiang, Y.; Lee, T. W.; Steenhuis, J.; Parnot, C.; Kobilka, B. K. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states J. Biol. Chem. 2004, 279, 686-691
158. Isogaya, M.; Yamagiwa, Y.; Fujita, S.; Sugimoto, Y.; Nagao, T.; Kurose, H. Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol Mol. Pharmacol. 1998, 54, 616-622
159. Jozwiak, K.; Plazinska, A.; Toll, L.; Jimenez, L.; Woo, A. Y.; Xiao, R. P.; Wainer, I. W. Effect of fenoterol stereochemistry on the β2 adrenergic receptor system: ligand-directed chiral recognition Chirality 2011, 23, E1-E6
160. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Edney, D. D.; Field, R. N.; Ford, A. J.; Guntrip, S. B.; Looker, B. E.; McLay, I. M.; Monteith, M. J.; Morrison, V. S.; Mutch, P. J.; Richards, S. A.; Sasse, R.; Smith, C. E. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups J. Med. Chem. 2009, 52, 2280-2288
161. Rezmann-Vitti, L. A.; Nero, T. L.; Jackman, G. P.; Machida, C. A.; Duke, B. J.; Louis, W. J.; Louis, S. N. Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor J. Med. Chem. 2006, 49, 3467-3477
162. Mohr, K.; Tränkle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise Br. J. Pharmacol. 2010, 159, 997-1008
163. Deupi, X.; Standfuss, J. Structural insights into agonist-induced activation of G-protein-coupled receptors Curr. Opin. Struct. Biol. 2011, 21, 541-551
164. Unal, H.; Karnik, S. S. Domain coupling in GPCRs: the engine for induced conformational changes Trends Pharmacol. Sci. 2012, 33, 79-88
165. Park, P. S. Ensemble of G protein-coupled receptor active states Curr. Med. Chem. 2012, 19, 1146-1154
166. Evans, B. A.; Sato, M.; Sarwar, M.; Hutchinson, D. S.; Summers, R. J. Ligand-directed signalling at beta-adrenoceptors Br. J. Pharmacol. 2010, 159, 1022-1038
167. Steyaert, J.; Kobilka, B. K. Nanobody stabilization of G protein-coupled receptor conformational states Curr. Opin. Struct. Biol. 2011, 21, 567-572
168. Beattie, D.; Beer, D.; Bradley, M. E.; Bruce, I.; Charlton, S. J.; Cuenoud, B. M.; Fairhurst, R. A.; Farr, D.; Fozard, J. R.; Janus, D.; Rosethorne, E. M.; Sandham, D. A.; Sykes, D. A.; Trifilieff, A.; Turner, K. L.; Wissler, E. An investigation into the structure activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol Bioorg. Med. Chem. 2012, 22, 6280-6285
169. Kahsai, A. W.; Xiao, K.; Rajagopal, S.; Ahn, S.; Shukla, A. K.; Sun, J.; Oas, T. G.; Lefkowitz, R. J. Multiple ligand-specific conformations of the β2-adrenergic receptor Nat. Chem. Biol. 2011, 7, 692-700
170. Kusiak, J. W.; Heja, G.; Pitha, J. Two beta-adrenergic pharmacophores on the same molecule. A set of agonist-antagonist combinations Biochem. Pharmacol. 1987, 36, 269-275
171. Rosenkilde, M. M.; Benned-Jensen, T.; Frimurer, T. M.; Schwartz, T. W. The minor binding pocket: a major player in 7TM receptor activation Trends Pharmacol. Sci. 2010, 31, 567-574
172. Granier, S.; Kobilka, B. A new era of GPCR structural and chemical biology Nat. Chem. Biol. 2012, 8, 670-673
173. Madala, P. K.; Fairlie, D. P.; Bodén, M. Matching cavities in G protein-coupled receptors to infer ligand-binding sites J. Chem. Inf. Model. 2012, 52, 1401-1410
174. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66
175. Isin, B.; Estiu, G.; Wiest, O.; Oltvai, Z. N. Identifying ligand binding conformations of the B2-adrenergic receptor by using its agonist as computational probes PLoS One 2012, 7, e50186
176. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194
177. Langmead, C. J.; Christopoulos, A. Supra-physiological efficacy at GPCRs: superstition or super agonists? Br. J. Pharmacol. 2013, 169, 353-356
178. Christopher, J. A.; Brown, J.; Doré, A. S.; Errey, J. C.; Koglin, M.; Marshall, F. H.; Myszka, D. G.; Rich, R. L.; Tate, C. G.; Tehan, B.; Warne, T.; Congreve, M. Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity aryl piperazine leads using structure-based drug design J. Med. Chem. 2013, 56, 3446-3455
179. Mistry, S. N.; Baker, J. G.; Fischer, P. M.; Hill, S. J.; Gardiner, S. M.; Kellam, B. Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists J. Med. Chem. 2013, 56, 3852-3865
180. Weiss, D. R.; Ahn, S.; Sassano, M. F.; Kleist, A.; Zhu, X.; Strachan, R.; Roth, B. L.; Lefkowitz, R. J.; Shoichet, B. K. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic g protein coupled receptor ACS Chem. Biol. 2013, 8, 1018-1026